Last update 01 Nov 2024

Immutep Australia Pty Ltd.

Subsidiary Company|
Australia

Overview

Related

1
Drugs associated with Immutep Australia Pty Ltd.
Eftilagimod alpha
Target
HLA class II antigen x LAG3
Mechanism
HLA class II antigen modulators [+3]
Active Org.
Immutep SAS [+4]
Originator Org.
Immutep Ltd.Immutep Ltd.
Active Indication
Metastatic breast cancer [+13]
Inactive Indication
COVID-19 [+5]
Drug Highest PhasePhase 2/3
First Approval Ctry. / Loc.-
First Approval Date-
1
Clinical Trials associated with Immutep Australia Pty Ltd.
NCT02676869 / CompletedPhase 1
A Multicentre, Open Label, Dose Escalation, Phase 1 Study in Patients With Unresectable or Metastatic Melanoma Receiving IMP321 (LAG-3Ig Fusion Protein-eftilagimod Alpha) as an Adjunctive Therapy to Anti-PD-1 Therapy With Pembrolizumab
100 Clinical Results associated with Immutep Australia Pty Ltd.
Login to view more data
0 Patents (Medical) associated with Immutep Australia Pty Ltd.
Login to view more data
100 Deals associated with Immutep Australia Pty Ltd.
Login to view more data
100 Translational Medicine associated with Immutep Australia Pty Ltd.
Login to view more data

Corporation Tree

Boost your research with our corporation tree data.
login
or
view full example data
Boost your research with our corporation tree data.

Pipeline

Pipeline Snapshot as of 23 Nov 2024

The statistics for drugs in the Pipeline is the current organization and its subsidiaries are counted as organizations,Early Phase 1 is incorporated into Phase 1, Phase 1/2 is incorporated into phase 2, and phase 2/3 is incorporated into phase 3
Other
1
Login to view more data

Current Projects

Drug(Targets)IndicationsGlobal Highest Phase
Eftilagimod alpha
 ( HLA class II antigen x LAG3 )		Unresectable Melanoma
More
Pending
Login to view more data

Deal

Boost your decision using our deal data.
login
or
view full example data
Boost your decision using our deal data.

Translational Medicine

Boost your research with our translational medicine data.
login
or
view full example data
Boost your research with our translational medicine data.

Profit

Explore the financial positions of over 360K organizations with Synapse.
login
or
view full example data
Explore the financial positions of over 360K organizations with Synapse.

Grant & Funding(NIH)

Access more than 2 million grant and funding information to elevate your research journey.
login
or
view full example data
Access more than 2 million grant and funding information to elevate your research journey.

Investment

Gain insights on the latest company investments from start-ups to established corporations.
login
or
view full example data
Gain insights on the latest company investments from start-ups to established corporations.

Financing

Unearth financing trends to validate and advance investment opportunities.
login
or
view full example data
Unearth financing trends to validate and advance investment opportunities.
Chat with Hiro
Get started for free today!
Accelerate Strategic R&D decision making with Synapse, PatSnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.
Start your data trial now!
Synapse data is also accessible to external entities via APIs or data packages. Empower better decisions with the latest in pharmaceutical intelligence.
Bio
Bio Sequences Search & Analysis
Sign up for free
Chemical
Chemical Structures Search & Analysis
Sign up for free